Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07095114 · ClinicalTrials.gov registry record · NA
A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients.
A NA study of Stage II Breast Cancer and Stage III Breast Cancer, sponsored by Barbara Ann Karmanos Cancer Institute.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT07095114: Recruiting NA study of Stage II Breast Cancer and Stage III Breast Cancer, sponsored by Barbara Ann Karmanos Cancer Institute.
NCT07095114 is a NA study of Stage II Breast Cancer and Stage III Breast Cancer that is actively recruiting participants, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 30 participants, below the 318-participant average among 30 other Stage II Breast Cancer trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07095114, a NA study of Stage II Breast Cancer and Stage III Breast Cancer, is actively recruiting participants, sponsored by Barbara Ann Karmanos Cancer Institute.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn if tattoos applied with Magic Ink is as safe as commercially available standard tattoo ink for the purpose of radiation in women with breast cancer undergoing radiation treatment. The main questions are: * Is the Magic Ink as safe as standard tattoo ink * Does Magic Ink continue to function and remain visible for radiation therapists during the treatment Participants will be consented and given a skin assessment. Once enrolled participants will be administered the Magic Ink tattoo instead of the standard tattoo ink in preparation for their radiation treatment. Participants will also complete a survey regarding body image. Skin assessment will occur again after the first week of radiation and at 3 months later. Throughout the radiation therapy the medical physicist will complete surveys about ease of set-up of the equipment.
Primary Outcome
Number of participants with treatment related adverse events as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v5.0)
Conditions Studied
Interventions
- OTHER Magic Ink
Study Locations (1)
Michigan
- Karmanos Cancer Institute - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-08-18 |
| Est. Completion | 2026-08-08 |
| Phase | NA |
What NCT07095114 shows while recruiting
NCT07095114 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 318-participant average among 30 other Stage II Breast Cancer trials with a reported enrollment target (91% lower).
The record links to 4 conditions, with Stage II Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Magic Ink is the first listed.
NCT07095114 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT07095114 about?
NCT07095114 is a clinical study titled "A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients.". The goal of this clinical trial is to learn if tattoos applied with Magic Ink is as safe as commercially available standard tattoo ink for the purpose of radiation in women with breast cancer undergoing radiation treatment. The main questions are: * Is the Magic Ink as safe as standard tattoo ink *...
What is the current status of trial NCT07095114?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2025-08-18. Estimated completion is 2026-08-08.
What conditions does trial NCT07095114 study?
This clinical trial studies the following conditions: Stage II Breast Cancer, Stage III Breast Cancer, Ductal Carcinoma In Situ, Stage I Breast Cancer.
What interventions are being tested in trial NCT07095114?
The interventions under investigation include: Magic Ink (OTHER).
Who is sponsoring clinical trial NCT07095114?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07095114 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage II Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07095114's enrollment target sits among peer trials
30 28th of 30 higher than 3 of 30 other Stage II Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stage II Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients
RECRUITING · NA
-
Improving Exercise Capacity With a Tailored Physical Activity Intervention
RECRUITING · NA
-
Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery
ACTIVE NOT RECRUITING · NA
-
A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)
ACTIVE NOT RECRUITING · NA
-
Researching the Effect of Exercise on Cancer
ACTIVE NOT RECRUITING · NA
-
Cytoxan, Epirubicin and Capecitabine in Women With Breast Cancer
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI